|
Chen et al.
10
|
2021 |
ctDNA, CEA, CT |
In the preoperative period, ctDNA was detectable in 64.2% of the patients; in the postoperative period, ctDNA negativity was associated with a recurrence-free survival rate of 89.4% in contrast to 39.9% of the ctDNA-positive patients. The ctDNA samples were collected in the preoperative, postoperative periods and six months after surgery serially every three months until month 24, or patient's withdrawal from the study, or death, and were analyzed using next-generation sequencing |
|
Henriksen et al.
11
|
2022 |
ctDNA, CEA, CT |
There was a recurrence rate of 80% in the ctDNA-positive patients in the postoperative period and, in this context, ctDNA exceeded the ≥ 70 age, T4, degree of tumor differentiation, and CEA as a predictor of recurrence-free survival; after adjuvant therapy, 100% of the patients who were not ctDNA-negative in the follow-up period experienced recurrence. The ctDNA samples were collected during the diagnosis, in the postoperative period, during adjuvant therapy and after its completion, and in routine follow-ups, every three months for up to three years, analyzed using next-generation sequencing |
|
McDuff et al.
12
|
2021 |
ctDNA, CEA, CT |
Resection rate R0 (macroscopically complete resection with histologically negative margins) was significantly higher among patients with undetectable preoperative ctDNA (88%) compared to those ctDNA-positive (44%). The ctDNA samples were collected, in a unique way, in the preoperative and postoperative periods, and analyzed using next-generation sequencing |
|
Reinert et al.
13
|
2019 |
ctDNA, CEA, CT |
The detection of ctDNA in stages II and III tumors was significantly higher than those in stage I; the mean time of detection of high ctDNA levels in patients who completed the definitive treatment until the evidence of recurrence through CT was 8.7 months. The ctDNA samples were collected before and after the surgical intervention, analyzed through next-generation sequencing, and serialized every three months until death, patient withdrawal from the study, or month 36 |
|
Tie et al.
14
|
2016 |
ctDNA, CEA, CT |
Radiological recurrence was detected in 78.6% of ctDNA-positive patients not treated with adjuvant therapy; in the follow-up period, ctDNA was more often positive than CEA at the time of recurrence, besides presenting elevation in its levels at a significantly longer time than CEA until the radiological evidence of tumor recurrence. The ctDNA samples were collected after surgical intervention, analyzed by a safe-sequencing system, and serialized every three months for up to two years |
|
Tie et al.
15
|
2019 |
ctDNA, CEA, CT |
Recurrence-free survival in three years was 33% for ctDNA-positive postoperative patients and 87% for ctDNA-negative patients; a similar pattern was also found after neoadjuvant therapy (50% and 85%, respectively). The ctDNA samples were collected uniquely, before and after the beginning of the pre-treatment (radiochemotherapy), and 4-10 weeks after surgical intervention, and were analyzed by a safe-sequencing system |
|
Tie et al.
16
|
2019 |
ctDNA, CEA, CT |
After surgery, three-year survival in ctDNA-positive patients was 47%; the post-surgical status of ctDNA had the strongest independent association with the recurrence-free interval. The ctDNA samples were collected uniquely after surgical intervention and at the end of the treatment, analyzed by a safe-sequencing system |
|
Wang et al.
17
|
2019 |
ctDNA, CEA, CT |
In the postoperative period, there was a positivity of ctDNA between 2 and 31 months before the radiological evidence of tumor recurrence; 100% of the patients who had recurrence presented ctDNA detectable in the follow-up period. The ctDNA samples were collected one month after surgical intervention, serialized every three to six months, and analyzed using a safe-sequencing system |
|
Zhou et al.
18
|
2021 |
ctDNA, CEA, CA19-9, CT |
The detection of ctDNA in the baseline was positively correlated with the occurrence of distant metastases in a shorter period than those patients whose ctDNA was undetectable. This correlation was positive at all times of dosage. CtDNA samples were collected serially in the baseline, during neoadjuvant radiochemotherapy, in the preoperative and postoperative period, and were analyzed using next-generation sequencing |
|
Huffman et al.
19
|
2022 |
ctDNA, CT |
CtDNA was present in about one-fifth of the patients in the postoperative setting, associated with a recurrence rate of 81.2%; in all analyzed scenarios, there was a similarity of results in the various tumor subtypes. The ctDNA samples were collected in the preoperative, postoperative, and serially during routine clinical follow-up at medical criteria, and were analyzed using next-generation sequencing |
|
Zhang et al.
20
|
2023 |
ctDNA, CT |
The three-year survival estimate for ctDNA-negative and ctDNA-positive patients was 73% and 34%, respectively, after neoadjuvant therapy and 68% and 38%, respectively, after surgery. The ctDNA samples were collected uniquely before neoadjuvant chemotherapy, after neoadjuvant chemotherapy, and after surgery, analyzed through next-generation sequencing |
|
Li et al.
21
|
2022 |
ctDNA, CT |
Recurrence-free survival in ctDNA-positive patients after adjuvant chemotherapy was 45.5%, in contrast to 72.7% of ctDNA-negative patients. The ctDNA samples were collected before and after chemotherapy in non-serial mode, analyzed through next-generation sequencing |
|
Pazdirek et al.
22
|
2020 |
ctDNA, CT |
The overall survival rate in patients whose ctDNA was negative was 91.2%. The subgroup rate of patients whose ctDNA was positive corresponded to 71.4%. CtDNA samples were collected serially before therapy and at the end of the first week. The technologies used for analysis were denaturant capillary electrophoresis and BEAMING assay |
Use of Circulating Tumor DNA in Prognostic Analysis of Patients with Solid Malignant Tumors of the Gastrointestinal Tract: Systematic Review
Thumbnail
Caption: ctDNA = circulating tumor DNA.